Cross-comparison of Two Quality of Life Instruments Used in a Randomized Study of Combination Chemotherapy in Advanced Breast Cancer

REFERENCES

• Tannock I. Editorial. Treating the patient, not just the cancer. New Engl J Med 1987; 317: 1534–5.
   Google Scholar
• Coates A, Gebski VM, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast can-cer. A comparison of intermittent and continuous strategies. New Engl J Med 1987; 317: 1490–5.
   Google Scholar
• Bell DR, Tannock IF, Boyd NF. Quality of life measurement in breast cancer patients. Br J Cancer 1985; 51: 577–80.
   PubMed Web of Science ®Google Scholar
• Baum M, Ebbs SR, Fallowfield LJ, Fraser SCA. Measure-ment of quality of life in advanced breast cancer. Acta Oncol 1990; 29: 391–5.
   PubMed Web of Science ®Google Scholar
• Fraser SCA, Ebbs SR, Dobbs HJ, Fallowfield LJ, Baum M. The design of advanced breast cancer trials. New approaches. Acta Oncol 1990; 29: 397–400.
   Google Scholar
• Donovan K, Sanson-Fisher R, Redman S. Measuring quality of life in cancer patients. A review. J Clin Oncol 1989; 7: 959–68.
   PubMed Web of Science ®Google Scholar
• McMillen C, Feigl P, Metch B, Hayden K, Meyskens FL Jr, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989; 81: 485–95.
   PubMedGoogle Scholar
• Schipper H, Levitt M. Quality of life in cancer trials: What is it? Why measure it? In: Ventafridda V, VanDam FSAM, Yancik R, Tamburini M, eds. International workshop on quality of life assessment and cancer treatment. Vol 1. Milan, 11–13 December 1985. Amsterdam: Excerpta Medica, 1986: 119–30.
   Google Scholar
• Aaronson NK. Quality of life: What is it? How should it be measured? Oncology 1988; 2: 69–74.
   PubMedGoogle Scholar
• Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure the quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109–12.
   Google Scholar
• Baum M, Priestman T, West R, Jones EM. A comparison of subjective responses in a trial comparing endocrine with cyto-toxic treatment in advanced carcinoma of the breast. In: Mouridsen H, Palshof T, eds. Breast cancer: experimental and clinical aspects. Oxford: Pergamon Press, 1980: 223–6.
   Google Scholar
• Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment of advanced breast cancer. Lancet 1976; i: 899–901.
   Google Scholar
• Priestman T, Baum M, Jones V, Forbes JF. Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. Br Med J 1977; 1: 1238–50.
   Google Scholar
• Henderson CI, Allegra JC, Woodcock T, et al. Randomised clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560–71.
   PubMed Web of Science ®Google Scholar
• Bennet JM, Hyman BM, Doroshow JH, et al. A randomised multicenter trial comparing mitoxantrone, cyclophosphamide and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611–20.
   Google Scholar
• Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Can Med Assoc J 1986; 134: 889–95.
   Google Scholar
• Glimelius B, Hoffman K, Olafsdottir M, Pdhlman L, Sloan PO, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomised comparison of two regimes. Eur J Cancer Clin Oncol 1989; 25: 829–35.
   PubMedGoogle Scholar
• Aaronson NK. Methodological issues in psychological oncol-ogy with special references to clinical trials. In: Ventafridda V, van Dam FSAM, Yancik R, et al., eds. Proceedings of the international workshop on quality of life assessment and cancer treatment. Amsterdam: Excerpta Medica, 1986: 29–41.
   Google Scholar
• Cella DF. Quality of life outcomes: measurement and valida-tion. Oncology 1996; 10: 233–46.
   PubMedGoogle Scholar
• Cohen J. A coefficient for nominal scales. Educ Psychol Meas 1960; 20: 37–46.
   Web of Science ®Google Scholar
• Landis JR, Koch GG. The measurement of observer agree-ment for categorical data. Biometrics 1977; 33: 159–74.
   PubMed Web of Science ®Google Scholar
• Fraser SCA, Ramirez AJ, Ebbs SR, et al. A daily diary for quality of life measurement in advanced breast cancer trials. Br J Cancer 1993; 67: 341–6.
   PubMed Web of Science ®Google Scholar
• Cuna GR, Pellegrini A. Effect of methyl-prednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled multicenter study. Eur J Cancer Clin Oncol 1989; 25: 1817–21.
   Google Scholar
• Beller E, Tattersall M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensi-tive advanced cancer: a randomised placebo-controlled trial. Ann Oncol 1997; 8: 277–83.
   PubMed Web of Science ®Google Scholar
• Aaronson A, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Bullinger M, Ahmedzai S. A modular ap-proach to quality-of-life assessment in cancer trials. Recent results. Cancer Res 1988; 111: 231–49.
   PubMedGoogle Scholar
• Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35: 185–8.
   Google Scholar
• Selby PJ, Chapman JA, Etazadi-Amoli J, Dalley D, Boyd NF. The development of a method for assessing the quality of life of cancer patients. Br J Cancer 1984; 50: 13–22.
   PubMed Web of Science ®Google Scholar
• Coates A, Glasziou P, McNeil D. On the receiving end—III. Measurement of quality of life during cancer chemotherapy. Ann Oncol 1990; 1: 213–7.
   Google Scholar
• Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10: 1833–8.
   PubMed Web of Science ®Google Scholar